You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Chemotherapy and other systemic treatment regimens may change due to COVID-19. Find out more at Systemic Treatment Regimens During COVID-19.

AZCTVENE

Cancer Type: Hematologic, Leukemia - Acute Myeloid (AML)      Intent: Palliative
Regimen Category: evidence-informed
Drugs Used:
venetoclax (Unfunded)
Funding:
New Drug Funding Program
    Azacitidine - Acute Myeloid Leukemia (AML)
New Drug Funding Program
    Azacitidine - Acute Myeloid Leukemia (AML) Greater Than 30% Blasts

You might also be interested in